Survival outcomes of surgery in patients with pulmonary large-cell neuroendocrine carcinoma: a retrospective single-institution analysis and literature review
Autor: | Chao Guo, Xiaoyun Zhou, Shanqing Li, Cheng Huang, Jiaqi Zhang, Yeye Chen, Hongsheng Liu, Zhenhuan Tian |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Male
medicine.medical_specialty Lung Neoplasms lcsh:Medicine Disease 030204 cardiovascular system & hematology Pulmonary large-cell neuroendocrine carcinoma Malignancy 03 medical and health sciences 0302 clinical medicine medicine Humans Pharmacology (medical) Stage (cooking) Risk factor Pathological Genetics (clinical) Retrospective Studies Bronchus Surgical treatment Lung business.industry Research lcsh:R General Medicine Large cell neuroendocrine carcinoma of the lung Middle Aged medicine.disease Prognosis Surgery Carcinoma Neuroendocrine Survival Rate medicine.anatomical_structure 030220 oncology & carcinogenesis Carcinoma Large Cell Female business |
Zdroj: | Orphanet Journal of Rare Diseases Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-9 (2021) |
ISSN: | 1750-1172 |
Popis: | BackgroundPulmonary large-cell neuroendocrine carcinoma (pLCNEC) is a very rare malignancy originating from the lung and bronchus, and its biological behaviour, clinical diagnosis, treatment and prognosis are poorly understood. Thus, the clinical characteristics and surgical treatment-related prognostic factors of this rare disorder must be explored.ResultsThe clinical data of 59 patients (48 males and 11 females) who were treated by surgery and diagnosed with pLCNEC by postoperative pathology at Peking Union Medical College Hospital from April 2004 to April 2019 were analysed retrospectively. The median patient age was 62 years (38–79 years), and the median duration of disease was 2 months (0.5–18 months). Compared with other lung malignancies, pLCNEC lacks specific clinical symptoms and imaging features, and preoperative biopsy pathology is often insufficient to confirm the diagnosis. The corresponding numbers of patients who were classified into stages I, II, III and IV according to the postoperative pathological tumour-nodal-metastasis stage were 25, 12, 15 and 7, respectively. The median overall survival was 36 months (0.9–61.1 months). The 1-year, 3-year and 5-year survival rates were 76.3%, 49% and 44.7%, respectively. The tumour stage exerted a significant effect on survival (Cox multivariate analysis p ConclusionsFor patients with resectable pLCNEC, multidisciplinary therapy based on surgery may have good survival benefits, and tumour stage is an independent risk factor for the prognosis of pLCNEC. |
Databáze: | OpenAIRE |
Externí odkaz: |